TOPAZ-1 Trial: Durvalumab and Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer

Posted: 02/08/2022 | By: Chase Doyle

Question 1 of 5

What is the 5-year relative survival rate for patients with localized extrahepatic bile duct cancers?

Choose 1